醒脑静联合纳洛酮对肝性脑病患者相关指标的影响

发布时间：2019-01-22 10:19

【摘要】：目的:探讨醒脑静联合纳洛酮对肝性脑病患者相关指标的影响。方法:回顾性分析76例肝性脑病患者资料,按用药的不同分为对照组(40例)和观察组(36例)。在常规治疗基础上,对照组患者给予纳洛酮注射液1 mg,加入10%葡萄糖溶液100 m L中,静脉滴注,每日2次;观察组患者在对照组治疗的基础上给予醒脑静注射液20 m L,加入0.9%氯化钠注射液250 m L中,静脉滴注,每日1次。两组疗程均为2周。观察两组患者治疗前后长谷川痴呆量表(HDS)评分、简易智力状态检查量表(MMSE)评分、血氨、β-内啡肽、C-反应蛋白(CRP)、白细胞介素6(IL-6)、IL-10、肿瘤坏死因子α(TNF-α)水平及不良反应发生情况。结果:治疗后,两组患者HDS评分、MMSE评分均显著高于同组治疗前,且观察组显著高于对照组;两组患者血氨、β-内啡肽、IL-6、CRP和TNF-α水平均显著低于同组治疗前,且观察组显著低于对照组,差异均有统计学意义(P0.05);两组患者治疗前后IL-10水平比较,差异均无统计学意义(P0.05)。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论:在常规治疗的基础上,醒脑静联合纳洛酮可显著改善肝性脑病患者的认知功能,降低外周血神经毒性物质及炎症因子水平,且未增加不良反应的发生。
[Abstract]:Objective: to investigate the effect of Xingnaojing combined with naloxone on related indexes in patients with hepatic encephalopathy. Methods: 76 patients with hepatic encephalopathy were analyzed retrospectively and divided into control group (40 cases) and observation group (36 cases). On the basis of routine treatment, the patients in the control group were treated with naloxone injection 1 mg, and 10% glucose solution 100ml, intravenous drip twice daily. Patients in the observation group were given Xingnaojing injection 20ml on the basis of treatment in the control group, added 0.9% sodium chloride injection 250ml, intravenous drip, once a day. The course of treatment was 2 weeks in both groups. The scores of (HDS), (MMSE), serum ammonia, 尾 -endorphin, (CRP), interleukin 6 (IL-6) and IL-10, were measured before and after treatment in the two groups with Hasegawa dementia scale, mini-mental state examination scale, serum ammonia, 尾 -endorphin, C-reactive protein (CRP), interleukin 6 (IL-6), and IL-10,. The level of tumor necrosis factor 伪 (TNF- 伪) and the occurrence of adverse reactions. Results: after treatment, the HDS score and MMSE score of the two groups were significantly higher than those of the same group before treatment, and the observation group was significantly higher than the control group. The levels of blood ammonia, 尾 -endorphin, IL-6,CRP and TNF- 伪 in the two groups were significantly lower than those in the same group before treatment, and those in the observation group were significantly lower than those in the control group (P0.05). There was no significant difference in IL-10 levels between the two groups before and after treatment (P0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). Conclusion: Xingnaojing combined with naloxone can significantly improve the cognitive function of patients with hepatic encephalopathy, decrease the levels of neurotoxic substances and inflammatory factors in peripheral blood, and do not increase the occurrence of adverse reactions.
【作者单位】：四川省医学科学院/四川省人民医院急诊ICU;
【分类号】：R575.3

【相似文献】